Safety and preliminary efficacy of plerixafor (mozobil) in combination with chemotherapy and G-CSF: An open-label, multicenter, exploratory trial in patients with multiple myeloma and non-Hodgkin's lymphoma undergoing stem cell mobilization

M. J. Dugan, Richard Maziarz, W. I. Bensinger, A. Nademanee, J. Liesveld, K. Badel, C. Dehner, C. Gibney, G. Bridger, G. Calandra

Research output: Contribution to journalArticle

109 Citations (Scopus)

Abstract

Plerixafor, a novel CXCR4 inhibitor, is effective in mobilizing PBSCs particularly when used in conjunction with G-CSF. In four cohorts, this pilot study explored the safety of plerixafor mobilization when incorporated into a conventional stem cell mobilization regimen of chemotherapy and G-CSF. Forty (26 multiple myeloma and 14 non-Hodgkin's lymphoma) patients were treated with plerixafor. Plerixafor was well tolerated and its addition to a chemo-mobilization regimen resulted in an increase in the peripheral blood CD34+ cells. The mean rate of increase in the peripheral blood CD34+ cells was 2.8 cells/μl/h pre- and 13.3 cells/μl/h post-plerixafor administration. Engraftment parameters were acceptable after myeloblative chemotherapy, with the median day for neutrophil and plt engraftment being day 11 (range 8-20 days) and day 13 (range 7-77 days), respectively. The data obtained from the analysis of the cohorts suggest that plerixafor can safely be added to chemotherapy-based mobilization regimens and may accelerate the rate of increase in CD34+ cells on the second day of apheresis. Further studies are warranted to evaluate the effect of plerixafor in combination with chemomobilization on stem cell mobilization and collection on the first and subsequent days of apheresis, and its impact on resource utilization.

Original languageEnglish (US)
Pages (from-to)39-47
Number of pages9
JournalBone Marrow Transplantation
Volume45
Issue number1
DOIs
StatePublished - Jan 2010

Fingerprint

Hematopoietic Stem Cell Mobilization
Granulocyte Colony-Stimulating Factor
Combination Drug Therapy
Multiple Myeloma
Non-Hodgkin's Lymphoma
Multicenter Studies
Safety
Blood Component Removal
Drug Therapy
Blood Cells
JM 3100
Neutrophils
Cohort Studies

Keywords

  • AMD3100
  • Auto-SCT
  • Mobilization
  • Multiple myeloma
  • Non-Hodgkin's lymphoma
  • Plerixafor

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Safety and preliminary efficacy of plerixafor (mozobil) in combination with chemotherapy and G-CSF : An open-label, multicenter, exploratory trial in patients with multiple myeloma and non-Hodgkin's lymphoma undergoing stem cell mobilization. / Dugan, M. J.; Maziarz, Richard; Bensinger, W. I.; Nademanee, A.; Liesveld, J.; Badel, K.; Dehner, C.; Gibney, C.; Bridger, G.; Calandra, G.

In: Bone Marrow Transplantation, Vol. 45, No. 1, 01.2010, p. 39-47.

Research output: Contribution to journalArticle

@article{d7f0a200263448d1bdfa0d9a6a15cf36,
title = "Safety and preliminary efficacy of plerixafor (mozobil) in combination with chemotherapy and G-CSF: An open-label, multicenter, exploratory trial in patients with multiple myeloma and non-Hodgkin's lymphoma undergoing stem cell mobilization",
abstract = "Plerixafor, a novel CXCR4 inhibitor, is effective in mobilizing PBSCs particularly when used in conjunction with G-CSF. In four cohorts, this pilot study explored the safety of plerixafor mobilization when incorporated into a conventional stem cell mobilization regimen of chemotherapy and G-CSF. Forty (26 multiple myeloma and 14 non-Hodgkin's lymphoma) patients were treated with plerixafor. Plerixafor was well tolerated and its addition to a chemo-mobilization regimen resulted in an increase in the peripheral blood CD34+ cells. The mean rate of increase in the peripheral blood CD34+ cells was 2.8 cells/μl/h pre- and 13.3 cells/μl/h post-plerixafor administration. Engraftment parameters were acceptable after myeloblative chemotherapy, with the median day for neutrophil and plt engraftment being day 11 (range 8-20 days) and day 13 (range 7-77 days), respectively. The data obtained from the analysis of the cohorts suggest that plerixafor can safely be added to chemotherapy-based mobilization regimens and may accelerate the rate of increase in CD34+ cells on the second day of apheresis. Further studies are warranted to evaluate the effect of plerixafor in combination with chemomobilization on stem cell mobilization and collection on the first and subsequent days of apheresis, and its impact on resource utilization.",
keywords = "AMD3100, Auto-SCT, Mobilization, Multiple myeloma, Non-Hodgkin's lymphoma, Plerixafor",
author = "Dugan, {M. J.} and Richard Maziarz and Bensinger, {W. I.} and A. Nademanee and J. Liesveld and K. Badel and C. Dehner and C. Gibney and G. Bridger and G. Calandra",
year = "2010",
month = "1",
doi = "10.1038/bmt.2009.119",
language = "English (US)",
volume = "45",
pages = "39--47",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Safety and preliminary efficacy of plerixafor (mozobil) in combination with chemotherapy and G-CSF

T2 - An open-label, multicenter, exploratory trial in patients with multiple myeloma and non-Hodgkin's lymphoma undergoing stem cell mobilization

AU - Dugan, M. J.

AU - Maziarz, Richard

AU - Bensinger, W. I.

AU - Nademanee, A.

AU - Liesveld, J.

AU - Badel, K.

AU - Dehner, C.

AU - Gibney, C.

AU - Bridger, G.

AU - Calandra, G.

PY - 2010/1

Y1 - 2010/1

N2 - Plerixafor, a novel CXCR4 inhibitor, is effective in mobilizing PBSCs particularly when used in conjunction with G-CSF. In four cohorts, this pilot study explored the safety of plerixafor mobilization when incorporated into a conventional stem cell mobilization regimen of chemotherapy and G-CSF. Forty (26 multiple myeloma and 14 non-Hodgkin's lymphoma) patients were treated with plerixafor. Plerixafor was well tolerated and its addition to a chemo-mobilization regimen resulted in an increase in the peripheral blood CD34+ cells. The mean rate of increase in the peripheral blood CD34+ cells was 2.8 cells/μl/h pre- and 13.3 cells/μl/h post-plerixafor administration. Engraftment parameters were acceptable after myeloblative chemotherapy, with the median day for neutrophil and plt engraftment being day 11 (range 8-20 days) and day 13 (range 7-77 days), respectively. The data obtained from the analysis of the cohorts suggest that plerixafor can safely be added to chemotherapy-based mobilization regimens and may accelerate the rate of increase in CD34+ cells on the second day of apheresis. Further studies are warranted to evaluate the effect of plerixafor in combination with chemomobilization on stem cell mobilization and collection on the first and subsequent days of apheresis, and its impact on resource utilization.

AB - Plerixafor, a novel CXCR4 inhibitor, is effective in mobilizing PBSCs particularly when used in conjunction with G-CSF. In four cohorts, this pilot study explored the safety of plerixafor mobilization when incorporated into a conventional stem cell mobilization regimen of chemotherapy and G-CSF. Forty (26 multiple myeloma and 14 non-Hodgkin's lymphoma) patients were treated with plerixafor. Plerixafor was well tolerated and its addition to a chemo-mobilization regimen resulted in an increase in the peripheral blood CD34+ cells. The mean rate of increase in the peripheral blood CD34+ cells was 2.8 cells/μl/h pre- and 13.3 cells/μl/h post-plerixafor administration. Engraftment parameters were acceptable after myeloblative chemotherapy, with the median day for neutrophil and plt engraftment being day 11 (range 8-20 days) and day 13 (range 7-77 days), respectively. The data obtained from the analysis of the cohorts suggest that plerixafor can safely be added to chemotherapy-based mobilization regimens and may accelerate the rate of increase in CD34+ cells on the second day of apheresis. Further studies are warranted to evaluate the effect of plerixafor in combination with chemomobilization on stem cell mobilization and collection on the first and subsequent days of apheresis, and its impact on resource utilization.

KW - AMD3100

KW - Auto-SCT

KW - Mobilization

KW - Multiple myeloma

KW - Non-Hodgkin's lymphoma

KW - Plerixafor

UR - http://www.scopus.com/inward/record.url?scp=75149188308&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=75149188308&partnerID=8YFLogxK

U2 - 10.1038/bmt.2009.119

DO - 10.1038/bmt.2009.119

M3 - Article

C2 - 19483760

AN - SCOPUS:75149188308

VL - 45

SP - 39

EP - 47

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 1

ER -